

# Christian Klein

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1242106/christian-klein-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229  
papers

12,586  
citations

49  
h-index

109  
g-index

304  
ext. papers

14,901  
ext. citations

6.2  
avg, IF

5.92  
L-index

#	Paper	IF	Citations
229	In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. <i>Science</i> , <b>2004</b> , 303, 844-8	33.3	3663
228	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. <i>Blood</i> , <b>2010</b> , 115, 4393-402	2.2	635
227	A transcriptionally and functionally distinct PD-1 CD8 T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. <i>Nature Medicine</i> , <b>2018</b> , 24, 994-1004	50.5	440
226	Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 1991-2005	15.9	295
225	Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 11187-92	11.5	289
224	Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. <i>Biochemistry</i> , <b>2001</b> , 40, 336-44	3.2	248
223	Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 2031-42	6.1	243
222	p53 contains large unstructured regions in its native state. <i>Journal of Molecular Biology</i> , <b>2002</b> , 322, 917-27	27.5	214
221	The N-terminal domain of p53 is natively unfolded. <i>Journal of Molecular Biology</i> , <b>2003</b> , 332, 1131-41	6.5	203
220	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1344-55	12.5	197
219	Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. <i>MAbs</i> , <b>2013</b> , 5, 22-33	6.6	193
218	A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3286-97	12.9	185
217	Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. <i>Cancer Cell</i> , <b>2017</b> , 31, 396-410	24.3	180
216	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 8600-6	5.4	179
215	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , <b>2013</b> , 122, 3482-91	2.2	172
214	Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. <i>Blood</i> , <b>2011</b> , 118, 358-67	2.2	168
213	Targeting the p53-MDM2 interaction to treat cancer. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 1415-9	8.7	158

212	Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6730-40	12.9	150
211	Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. <i>Protein Engineering, Design and Selection</i> , <b>2016</b> , 29, 457-466	1.9	145
210	Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. <i>MAbs</i> , <b>2012</b> , 4, 653-63	6.6	130
209	Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. <i>Oncolmunology</i> , <b>2017</b> , 6, e1277306	7.2	126
208	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	116
207	Targeting key angiogenic pathways with a bispecific CrossMAB optimized for neovascular eye diseases. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 1265-1288	12	111
206	Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. <i>Journal of Immunology</i> , <b>2014</b> , 192, 2252-60	5.3	109
205	Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 178-85	6.1	106
204	Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 295-306	4.5	103
203	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	92
202	The use of CrossMAB technology for the generation of bi- and multispecific antibodies. <i>MAbs</i> , <b>2016</b> , 8, 1010-20	6.6	86
201	p53--a natural cancer killer: structural insights and therapeutic concepts. <i>Angewandte Chemie - International Edition</i> , <b>2006</b> , 45, 6440-60	16.4	85
200	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4785-4797	12.9	84
199	A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 129-140	7.4	80
198	A human immunodeficiency syndrome caused by mutations in CARMIL2. <i>Nature Communications</i> , <b>2017</b> , 8, 14209	17.4	79
197	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Advances in Therapy</i> , <b>2017</b> , 34, 324-356	4.1	79
196	Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. <i>Rheumatology</i> , <b>2017</b> , 56, 1227-1237	3.9	78
195	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , <b>2019</b> , 133, 1964-1976	2.2	72

194	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , <b>2016</b> , 14, 1748-1760	10.6	69
193	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukemia (P-ALL). <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 2004-2014	4.5	68
192	RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 946-57	6.1	67
191	NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 49020-7	5.4	67
190	CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. <i>Onc Immunology</i> , <b>2016</b> , 5, e1203498	7.2	65
189	BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 3439-50	5.4	64
188	The low molecular weight proteome of Halobacterium salinarum. <i>Journal of Proteome Research</i> , <b>2007</b> , 6, 1510-8	5.6	60
187	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 778-83	8.9	59
186	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. <i>Blood</i> , <b>2017</b> , 129, 2636-2644	2.2	58
185	Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>Journal of Autoimmunity</i> , <b>2015</b> , 56, 66-80	15.5	57
184	A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. <i>PLoS ONE</i> , <b>2013</b> , 8, e54923	3.7	57
183	KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. <i>Journal of Immunology</i> , <b>2014</b> , 192, 5618-24	5.3	56
182	High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 37390-401	5.4	56
181	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , <b>2019</b> , 154, 21-31	4.6	51
180	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <i>Blood</i> , <b>2011</b> , 117, 510-8	2.2	49
179	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 2500-5	1.9	48
178	A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. <i>Journal of Autoimmunity</i> , <b>2018</b> , 95, 1-14	15.5	48
177	In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4417-27	12.9	47

176	Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. <i>ACS Medicinal Chemistry Letters</i> , <b>2013</b> , 4, 660-5	4.3	46
175	A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. <i>Oncogene</i> , <b>2013</b> , 32, 5593-601	9.2	45
174	A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 18693-706	5.4	43
173	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 133, 2765-2775	2.2	42
172	Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. <i>Angewandte Chemie - International Edition</i> , <b>2005</b> , 44, 5247-51	16.4	42
171	Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2151-5160	1.9	40
170	p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	40
169	Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. <i>Archives of Biochemistry and Biophysics</i> , <b>2012</b> , 526, 206-18	4.1	39
168	Obinutuzumab in hematologic malignancies: lessons learned to date. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 784-92	14.4	37
167	Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin lymphomas: a glycoengineered type II CD20 antibody. <i>Oncology Research and Treatment</i> , <b>2015</b> , 38, 185-92	2.8	36
166	CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. <i>Blood</i> , <b>2011</b> , 118, 5178-88	2.2	36
165	Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. <i>Blood Cancer Journal</i> , <b>2013</b> , 3, e131	7	35
164	An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. <i>Journal of Medicinal Chemistry</i> , <b>2007</b> , 50, 4382-7	8.3	34
163	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 541-551	11.5	34
162	Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. <i>Protein Engineering, Design and Selection</i> , <b>2012</b> , 25, 551-9	1.9	32
161	Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3325-3333	12.9	31
160	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4634-4643	12.9	30
159	Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2234-42	7.5	30

158	Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.. <i>Blood</i> , <b>2006</b> , 108, 229-229	2.2	30
157	Boosting T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. <i>OncImmunology</i> , <b>2019</b> , 8, 1554175	7.2	30
156	Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, 364	9.7	29
155	Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model. <i>Circulation</i> , <b>2019</b> , 139, 2049-2063	16.7	29
154	Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin $\alpha$ B. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 467-72	8.9	28
153	Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death. <i>EMBO Molecular Medicine</i> , <b>2013</b> , 5, 1821-34	12	28
152	New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 808-820	4.5	26
151	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 151-155	8.9	26
150	Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. <i>PLoS ONE</i> , <b>2013</b> , 8, e61953	3.7	26
149	XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. <i>MAbs</i> , <b>2016</b> , 8, 811-27	6.6	25
148	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 2036-2051	12.5	24
147	Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. <i>Journal of Immunology</i> , <b>2013</b> , 191, 3634-40	5.3	24
146	A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. <i>Microcirculation</i> , <b>2011</b> , 18, 598-607	2.9	24
145	A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. <i>Leukemia</i> , <b>2017</b> , 31, 1611-1621	10.7	23
144	Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. <i>MAbs</i> , <b>2019</b> , 11, 621-631	6.6	22
143	Activatory and inhibitory Fc $\gamma$ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 5424-37	5.4	22
142	Short-hairpin-RNA-mediated silencing of fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. <i>Biotechnology and Applied Biochemistry</i> , <b>2009</b> , 53, 31-7	2.8	22
141	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. <i>OncImmunology</i> , <b>2016</b> , 5, e1062969	7.2	21

140	Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry. <i>MABs</i> , <b>2016</b> , 8, 49-55	6.6	21
139	Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. <i>Leukemia Research</i> , <b>2013</b> , 37, 440-6	2.7	21
138	Proteophosphoglycans of <i>Leishmania mexicana</i> . Molecular cloning and characterization of the <i>Leishmania mexicana</i> ppg2 gene encoding the proteophosphoglycans aPPG and pPPG2 that are secreted by amastigotes and promastigotes. <i>Biochemical Journal</i> , <b>1999</b> , 344 Pt 3, 787-95	3.8	21
137	Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). <i>European Journal of Haematology</i> , <b>2016</b> , 97, 461-470	3.8	21
136	DNA hypomethylating agents increase activation and cytolytic activity of CD8 T cells. <i>Molecular Cell</i> , <b>2021</b> , 81, 1469-1483.e8	17.6	19
135	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer <b>2020</b> , 8,		18
134	A Novel Synthesis of Highly Substituted Perhydropyrrolizines, Perhydroindolizines, and Pyrrolidines: Inhibition of the Peptidyl-Prolyl cis/trans Isomerase (PPIase) Pin1. <i>Helvetica Chimica Acta</i> , <b>2007</b> , 90, 217-259	2	18
133	Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. <i>PLoS ONE</i> , <b>2011</b> , 6, e16596	3.7	18
132	Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. <i>Journal of Immunotherapy</i> , <b>2016</b> , 39, 279-89	5	18
131	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 79-87	8.7	18
130	The PET-Tracer Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. <i>Cancer Research</i> , <b>2020</b> , 80, 2903-2913	10.1	17
129	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. <i>Nature Communications</i> , <b>2020</b> , 11, 3196	17.4	17
128	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5890-5900	12.9	17
127	Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , <b>2017</b> , 28, iii151	10.3	17
126	CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. <i>Blood</i> , <b>2016</b> , 128, 1836-1836	2.2	17
125	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 737-747	3.9	16
124	TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. <i>Protein Engineering, Design and Selection</i> , <b>2016</b> , 29, 467-475	1.9	16
123	Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. <i>MABs</i> , <b>2016</b> , 8, 562-73	6.6	15

122	Bispecific antibody derivatives based on full-length IgG formats. <i>Methods in Molecular Biology</i> , <b>2012</b> , 901, 247-63	1.4	15
121	Proteophosphoglycans of <i>Leishmania mexicana</i> . Identification, purification, structural and ultrastructural characterization of the secreted promastigote proteophosphoglycan pPPG2, a stage-specific glycoisoform of amastigote aPPG. <i>Biochemical Journal</i> , <b>1999</b> , 344 Pt 3, 775-86	3.8	15
120	Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 699-707	1.9	14
119	Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 575737	5.3	14
118	Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 764-76	12.5	13
117	Solution structure and binding specificity of the p63 DNA binding domain. <i>Scientific Reports</i> , <b>2016</b> , 6, 26707	4.9	13
116	Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly. <i>Protein Engineering, Design and Selection</i> , <b>2018</b> , 31, 289-299	1.9	13
115	The PI3K-selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. <i>Journal of Immunology</i> , <b>2018</b> , 200, 2304-2312	5.3	12
114	GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.. <i>Blood</i> , <b>2007</b> , 110, 2348-2348	2.2	12
113	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , <b>2020</b> , 7, e649-e659	14.6	12
112	Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. <i>BioMed Research International</i> , <b>2018</b> , 2018, 1023490	3	12
111	Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers. <i>Blood Cancer Journal</i> , <b>2015</b> , 5, e367	7	11
110	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. <i>Oncotarget</i> , <b>2017</b> , 8, 113895-113909	3.3	11
109	The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 826-836	9.5	11
108	Response to: monoclonal antibodies targeting CD20. <i>MAbs</i> , <b>2013</b> , 5, 337-8	6.6	10
107	p53 ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte. <i>Angewandte Chemie</i> , <b>2006</b> , 118, 6590-6611	3.6	10
106	214 POSTER Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor. <i>European Journal of Cancer, Supplement</i> , <b>2006</b> , 4, 66-67	1.6	10
105	A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2130-42	6.1	10



104	Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. <i>Nature Communications</i> , <b>2021</b> , 12, 1237	17.4	10
103	Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. <i>Oncotarget</i> , <b>2018</b> , 9, 7162-7174	3.3	10
102	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , <b>2021</b> , 10,	8.9	10
101	Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5811-9	12.9	9
100	Isolation and characterization of glycosylphosphatidylinositol-anchored, mucin-like surface glycoproteins from bloodstream forms of the freshwater-fish parasite <i>Trypanosoma carassii</i> . <i>Biochemical Journal</i> , <b>2000</b> , 345, 693	3.8	9
99	Proteophosphoglycans of <i>Leishmania mexicana</i> . <i>Biochemical Journal</i> , <b>1999</b> , 344, 775	3.8	9
98	Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products. <i>Protein Engineering, Design and Selection</i> , <b>2017</b> , 30, 649-656	1.9	9
97	Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN $\gamma$ /CXCL10-dependent peripheral T cell recruitment in humanized murine model. <i>PLoS ONE</i> , <b>2021</b> , 16, e0241091	3.7	9
96	GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. <i>Haematologica</i> , <b>2018</b> , 103, e78-e81	6.6	9
95	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1943	8.4	8
94	Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. <i>Blood</i> , <b>2010</b> , 116, 3373-3374	2.2	8
93	Proteophosphoglycans of <i>Leishmania mexicana</i> . <i>Biochemical Journal</i> , <b>1999</b> , 344, 787	3.8	8
92	How to outsmart NK cell tolerance. <i>Oncot Immunology</i> , <b>2015</b> , 4, e1016708	7.2	7
91	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
90	Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1482-1485	1.9	7
89	S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer <b>2014</b> , 2,		7
88	Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer. <i>Blood</i> , <b>2013</b> , 122, 2278-2278	2.2	7
87	Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 3952-3960	3.9	7

86	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody. <i>Blood</i> , <b>2021</b> ,	2.2	7
85	DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity. <i>MAbs</i> , <b>2019</b> , 11, 1402-1414	6.6	6
84	CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to cytokine stimulation via PI3K/mTOR axis. <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 501-512	7.4	6
83	Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation. <i>Chemistry and Biology</i> , <b>2014</b> , 21, 357-68		6
82	Anti-CD20 treatment for B-cell malignancies: current status and future directions. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 161-181	5.4	6
81	Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. <i>MAbs</i> , <b>2021</b> , 13, 1967714	6.6	6
80	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. <i>MAbs</i> , <b>2021</b> , 13, 1913791	6.6	6
79	In vitro folding and characterization of the p53 DNA binding domain. <i>Biological Chemistry</i> , <b>2004</b> , 385, 95-102	4.5	5
78	Backbone 1H, 13C and 15N resonance assignments for the 25.8 kDa DNA binding domain of the human p63 protein. <i>Journal of Biomolecular NMR</i> , <b>2003</b> , 26, 377-8	3	5
77	Kooperative Bindung von p53 an DNA: Regulation durch Protein-Protein-Wechselwirkung unter Bildung einer doppelten Salzbrücke. <i>Angewandte Chemie</i> , <b>2005</b> , 117, 5381-5386	3.6	5
76	Abstract 2270: RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells <b>2020</b> ,		5
75	Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs. the Type I CD20 Antibodies Rituximab and Ofatumumab. <i>Blood</i> , <b>2010</b> , 116, 3925-3925	2.2	5
74	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies <b>2021</b> , 9,		5
73	Targeting key angiogenic pathways with a bispecific CrossMab optimized for neovascular eye diseases. <i>EMBO Molecular Medicine</i> , <b>2017</b> , 9, 985	12	4
72	Combination therapy with the type II anti-CD20 antibody obinutuzumab. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 1145-1162	5.9	4
71	Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies. <i>Blood</i> , <b>2013</b> , 122, 4412-4412	2.2	4
70	Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo. <i>Blood</i> , <b>2014</b> , 124, 1765-1765	2.2	4
69	The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab. <i>Blood</i> , <b>2014</b> , 124, 3342-3342	2.2	4

68	A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2021</b> , 99, 832-843	4.6	4
67	A modular and controllable T cell therapy platform for acute myeloid leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 2243-2257	4.7	4
66	P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. <i>Protein Engineering, Design and Selection</i> , <b>2019</b> , 32, 207-218	1.9	3
65	Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab. <i>Scientific Reports</i> , <b>2019</b> , 9, 13675	4.9	3
64	RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies. <i>Blood</i> , <b>2020</b> , 136, 40-40	2.2	3
63	Abstract 3629: Engineering a novel asymmetric head-to-tail 2+1 T-cell bispecific (2+1 TCB) IgG antibody platform with superior T-cell killing compared to 1+1 asymmetric TCBs <b>2017</b> ,		3
62	Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells <b>2017</b> ,		3
61	Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism <b>2019</b> ,		3
60	A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys. <i>Blood</i> , <b>2015</b> , 126, 2998-2998	2.2	3
59	Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. <i>Lung Cancer</i> , <b>2021</b> , 155, 10-19	5.9	3
58	Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. <i>Onc Immunology</i> , <b>2021</b> , 10, 1869389	7.2	3
57	Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy. <i>Rheumatology</i> , <b>2021</b> ,	3.9	3
56	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.. <i>Onc Immunology</i> , <b>2022</b> , 11, 2039432	7.2	3
55	OP0159 Improving B-Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Resistance To Rituximab and The Potential of Obinutuzumab. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 116.1-116	2.4	2
54	PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species. <i>Journal of Pharmaceutical Sciences</i> , <b>2019</b> , 108, 3729-3736	3.9	2
53	Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma <b>2014</b> , 1695-1732		2
52	653 Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release <b>2020</b> ,		2
51	Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies. <b>2013</b> ,		2

50	Abstract LB-236: M4-3-ML2, a novel glycoengineered humanized IgG1 antibody, targeting a membrane-proximal epitope of MCSP/CSPG4 exhibits potent ADCC induction in vitro and in vivo anti-tumoral efficacy in disseminated melanoma models <b>2012</b> ,		2
49	Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo <b>2014</b> ,		2
48	Abstract 650: KIR/HLA interactions negatively affect rituximab, but not GA101 (obinutuzumab)-induced ADCC <b>2014</b> ,		2
47	Abstract 3658: Dendritic cells dictate the responsiveness of PD-L1 blockade in cancer <b>2017</b> ,		2
46	Abstract 1788: Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab <b>2018</b> ,		2
45	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 41-42	2.2	2
44	Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?. <i>Blood</i> , <b>2014</b> , 124, 1980-1980	2.2	2
43	CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo. <i>Blood</i> , <b>2015</b> , 126, 4157-4157	2.2	2
42	The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models. <i>Blood</i> , <b>2016</b> , 128, 4178-4178	2.2	2
41	Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
40	A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis. <i>AAPS Journal</i> , <b>2021</b> , 24, 7	3.7	2
39	Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide. <i>Blood</i> , <b>2019</b> , 134, 4450-4450	2.2	2
38	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2371-2381	6.1	2
37	Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo. <i>MAbs</i> , <b>2020</b> , 12, 1834-1818	6.6	1
36	Antikörper Die Krebsmedikamente. Gezielt wirksame Biomedizin. <i>Chemie in Unserer Zeit</i> , <b>2009</b> , 43, 328-338	0.2	1
35	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. <b>2022</b> , 10,		1
34	Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.. <i>Theranostics</i> , <b>2022</b> , 12, 1373-1387	12.1	1
33	141 PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants <b>2020</b> , 8, A155-A155		1

32	Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 3963-3963	2.2	1
31	Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263. <i>Blood</i> , <b>2010</b> , 116, 3915-3915	2.2	1
30	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. <i>Oncotarget</i> , <b>2020</b> , 11, 3035-3047	3.3	1
29	Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist. <i>Blood</i> , <b>2021</b> , 138, 1178-1178	2.2	1
28	Disparity in Peripheral and Renal B-cell Depletion with Rituximab in Systemic Lupus Erythematosus: an Opportunity for Obinutuzumab?. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
27	From Degraders to Molecular Glues: New Ways of Breaking Down Disease-Associated Proteins <b>2021</b> , 47-85		1
26	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , <b>2021</b> , 5, 2945-2957	7.8	1
25	Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells. <i>Journal of Immunology</i> , <b>2021</b> , 207, 493-504	5.3	1
24	Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 29-30	2.2	0
23	Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL). <i>Blood</i> , <b>2020</b> , 136, 23-24	2.2	0
22	CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins. <i>MAbs</i> , <b>2020</b> , 12, 1840709	6.6	0
21	Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , <b>2021</b> , 5, 2935-2944	7.8	0
20	Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia <b>2018</b> , 245-289		
19	Activation of cytomegalovirus-specific CD8 T-cell response by antibody-mediated peptide-major histocompatibility class I complexes. <i>Onc Immunology</i> , <b>2016</b> , 5, e1052930	7.2	
18	Ocrelizumab: A New Generation of anti-CD20 mAb for Treatment of Multiple Sclerosis <b>2019</b> , 169-199		
17	PD-1 IMMUNE CHECKPOINT BLOCKADE IMPROVES ANTI-CD20 BASED IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , <b>2017</b> , 35, 257-258	1.3	
16	Glycoengineering of Therapeutic Antibodies. <i>Arzneimittelforschung</i> , <b>2012</b> , 62, S4-S5		
15	Targeting the p53/MDM2 Pathway for Cancer Therapy <b>2008</b> , 19-56		

- 14 Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma. *Blood*, **2018**, 132, 5381-5381 2.2
- 13 PF207 TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN. *HemaSphere*, **2019**, 3, 56 0.3
- 12 ADCC Induced By Monoclonal Anti-CD20 Antibodies in a 3D Follicular Lymphoma model : Signaling and Spatial Localization. *Blood*, **2014**, 124, 3114-3114 2.2
- 11 Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity. *Blood*, **2014**, 124, 1780-1780 2.2
- 10 Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins. *Blood*, **2015**, 126, 1550-1550 2.2
- 9 CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism. *Blood*, **2010**, 116, 3979-3979 2.2
- 8 Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies. *Blood*, **2010**, 116, 4285-4285 2.2
- 7 Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. *Blood*, **2010**, 116, 2459-2459 2.2
- 6 Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2. *Blood*, **2010**, 116, 4304-4304 2.2
- 5 Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model. *Blood*, **2012**, 120, 4868-4868 2.2
- 4 L4 Synthetic agonistic receptor-activating BiTEs is a modular platform for the efficient targeting of acute myeloid leukemia **2020**, 8, A2.2-A3
- 3 P06.01 Bispecific antibody-driven synthetic agonistic receptor transduced T cells mediate specific and conditional therapy in melanoma cancer models **2020**, 8, A41.2-A42
- 2 L2 In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific CD20-TCB antibody **2020**, 8, A1.2-A1
- 1 Discovery and Development of Emicizumab (HEMLIBRA  $\square$ ): A Humanized Bispecific Antibody to Coagulation Factors IXa and X with a Factor VIII Cofactor Activity **2021**, 221-248